ADx is developing a broad spectrum of biomarkers applicable in neurodegenerative diseases ranging from Alzheimer’s disease to traumatic brain injury to Parkinson’s disease. All markers are detected in the cerebrospinal fluid (CSF) unless noted otherwise.
|Discovery & concept||Materials||Feasibility assay design||Prototype||Analytical qualification||Analytical validation + clinical qualification||RUO / CE / SFDA|
|TRAUMATIC BRAIN INJURY MARKERS|
Some of the ADx markers were developed and commercialized in collaboration with our partners. The new generation of Alzheimer's disease diagnostics, using Aβ 1-40, Aβ 1-42 and total tau, is now available through our partner EuroImmun a Perkin Elmer company. For the development of high sensitive blood tests, we are collaborating with IVD enterprise Quanterix.
Other programs enjoy the financial support from various instances who believe in the know-how and technology of ADx. The development of α-synuclein as a marker for Parkinson's disease is supported by the Michael J. Fox Foundation while our advances with the marker neurogranin are supported by the IWT/VLAIO.